Yunnan Cancer Hospital

What Yunnan Cancer Hospital does

Yunnan Cancer Hospital is a public tertiary Grade-A oncology specialty hospital located in Kunming, Yunnan Province, China. Founded in 1984, it operates as both the Yunnan Provincial Tumor Hospital and the Third Affiliated Hospital of Kunming Medical University, serving as the provincial flagship institution for cancer prevention, diagnosis, treatment, rehabilitation, research, and professional training. Its core clinical product is comprehensive oncology care delivered through nationally designated key clinical specialties in Oncology, Thoracic Surgery, and Gastrointestinal Surgery, supported by specialized centers in Tumor Biotherapy, Nuclear Medicine, Molecular Diagnostics, and a Phase I Clinical Trial Ward — a configuration that is unique in Southwest China. The hospital is also integrated into the Peking University Cancer Hospital (PUCH) national network through the Beijing University Cancer Hospital Yunnan Hospital, which entered full operations on May 23, 2026.

The business model is that of a public Chinese tertiary hospital: revenue is generated primarily through medical service fees regulated by the National Health Commission and settled via China's basic medical insurance scheme, supplemented by provincial government budget allocations for its role as a national key clinical specialty host. Patient flow is driven by the hospital's geographic monopoly as Yunnan's only tertiary cancer specialty hospital, supplemented by referral relationships with PUCH and regional medical institutions, and increasingly by a new Free Trade Hospital channel that opened for surgical services on May 21, 2026. Recent digital initiatives — including an AI-driven medical record quality control system, a tumor diagnosis standardization platform, and a somatic cell therapy management system — point to operational modernization rather than revenue model change.

The institution is not a commercial enterprise in the conventional sense; it does not raise venture funding, issue equity, or seek M&A outcomes, and the listed for-profit designation and 1–10 employee count in the source data appear inconsistent with its actual scale as a major tertiary academic medical center.

Name

Yunnan Cancer Hospital

Legal name

北京大学肿瘤医院云南医院（云南省肿瘤医院）

Website

https://ynszlyy.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

1–10 employees

Short description

Yunnan Cancer Hospital is a public tertiary Grade-A oncology specialty hospital in Kunming, founded 1984 and affiliated with Kunming Medical University and Peking University Cancer Hospital, serving as Yunnan's flagship cancer prevention, diagnosis, treatment, and research institution.

Ownership category

akta.pro rank

Product category

Cancer Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), General Medical and Surgical Hospitals (622110), Hospitals (622)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Health Services (8000)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC)

Keywords

• Oncology hospital services
• Cancer treatment
• Radiation therapy
• Clinical trials
• Tumor diagnostics

Headquarters

HQ city

Yünnan

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Medical Services Revenue: Public hospital providing comprehensive medical services to cancer patients including outpatient, inpatient, surgery, chemotherapy, radiation therapy, and diagnostic services. Revenue generated from medical service fees regulated by Chinese healthcare pricing policies.

Distribution channels1 record

Marketing channels4 records

Core offering

Yunnan Cancer Hospital, also known as Beijing University Cancer Hospital Yunnan Hospital (北京大学肿瘤医院云南医院), is a specialized oncology hospital founded in 1984 in Kunming, Yunnan Province. It delivers comprehensive cancer prevention, early screening, diagnosis, and treatment services through multidisciplinary care including surgery, chemotherapy, radiation therapy, interventional radiology, biological therapy, and palliative care. The hospital also conducts oncology professional training and cancer prevention research, and operates as the Third Affiliated Hospital of Kunming Medical University (昆明医科大学第三附属医院).

Product overview

北京大学肿瘤医院云南医院（云南省肿瘤医院）is a specialized oncology hospital founded in 1984, located in Kunming, Yunnan Province. The hospital operates as a comprehensive cancer center offering prevention, diagnosis, treatment services, and high-level oncology professional training. The hospital includes specialized departments such as the Phase I Clinical Trial Ward, Tumor Biotherapy Center, Clinical Nutrition Department, Nuclear Medicine Department, and Critical Care Medicine. It also features a Free Trade Hospital (自贸医院) and serves as Kunming Medical University's Third Affiliated Hospital. The hospital has national key clinical specialties including Oncology, Thoracic Surgery, and Gastrointestinal Surgery, as well as provincial key clinical specialties covering various cancer types and treatment modalities.

Differentiator

Problem solved

Functional benefit

Products and services

• Yunnan Cancer Hospital (Beijing University Cancer Hospital Yunnan Hospital) A specialized cancer hospital founded in 1984 providing cancer prevention, diagnosis, treatment, high-level oncology professional training, and cancer prevention research to patients in Yunnan Province and southwestern China.
• Phase I Clinical Trial Ward (I期临床试验病房) Dedicated Phase I clinical trial ward for conducting early-phase clinical research on cancer treatments, serving oncology researchers, pharmaceutical sponsors, and eligible trial participants.
• Tumor Biotherapy Center (肿瘤生物治疗中心) Specialized center for tumor biotherapy and cell therapy research and clinical application, led by Director Yao Hong, serving cancer patients requiring biological and cell-based therapies.
• Clinical Nutrition Department (临床营养科) Provides comprehensive nutritional treatment for tumor patients, specializing in full-course and complex oncology nutrition support, directed by Zhou Lan.
• Nuclear Medicine Department (核医学科) Provides SPECT and PET/CT imaging and radionuclide therapy for tumor diagnosis and treatment including thyroid cancer, hyperthyroidism, and bone metastasis, led by Director Deng Zhiyong.
• Critical Care Medicine Department (重症医学科) Specialized in diagnosis and treatment of tumor-related acute and critical conditions, including perioperative management and severe pneumonia, led by Director Xiao Yun.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Peking University Cancer Hospital (北京大学肿瘤医院)coreStrategic or Co-development PartnerPeking University Cancer Hospital Yunnan Hospital (北京大学肿瘤医院云南医院) operates as a branch/collaboration with Peking University Cancer Hospital, providing Beijing-level medical expertise and brand affiliation. The partnership enables knowledge sharing, expert deployment, and coordinated cancer treatment standards.

Scale indicators1 record

Recent moves8 records

Expansion highlights5 records

Direct peers

• Tianjin Medical University Cancer Hospital: National clinical key specialty cancer hospital in Tianjin. Comparable as a regional comprehensive cancer center with multidisciplinary treatment, clinical trials, and academic medical integration.
• Chinese Academy of Medical Sciences Cancer Hospital: National cancer center in Beijing operating under the Chinese Academy of Medical Sciences. Comparable as a top-tier comprehensive oncology hospital with strong research orientation and clinical trial capabilities.
• Peking University Cancer Hospital: Parent and strategic partner institution; one of China's top national cancer centers. Directly comparable as a comprehensive oncology hospital offering prevention, diagnosis, treatment, and research across all major cancer types.
• Fudan University Shanghai Cancer Center: Tier-1 city comprehensive cancer center with national recognition across multiple oncology specialties. Comparable as a leading academic cancer hospital with integrated clinical, research, and training functions.
• Sun Yat-sen University Cancer Center: National-level cancer hospital in Guangzhou with comprehensive multidisciplinary oncology services, clinical trials, and research. Closely comparable in scale and specialty breadth as a leading Chinese cancer center.
• Zhejiang Cancer Hospital: Provincial-level cancer hospital in Hangzhou with national key clinical specialty designations. Comparable as a regional comprehensive oncology center serving a defined provincial catchment.
• Guangdong Provincial People's Hospital Cancer Center: Provincial cancer treatment center in Guangzhou offering comprehensive oncology services including surgery, chemotherapy, radiation, and biological therapy. Comparable as a multi-specialty cancer hospital within a major academic medical system.

Broad incumbents

• MD Anderson Cancer Center: Global leader in comprehensive cancer care, research, and education. Comparable as a benchmark for the full-service academic cancer center model that Yunnan Cancer Hospital aspires to emulate at a regional level.

Regional players

• West China Hospital (Sichuan University): Major southwestern China academic medical center with growing oncology capabilities. Comparable as a regional competitor for complex cancer cases in southwest China.
• The First Affiliated Hospital of Kunming Medical University: Largest general hospital in Yunnan Province with growing oncology services. Comparable as a local Kunming competitor with overlapping patient catchment and academic medical affiliations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yunnan Cancer Hospital